Pelthos Therapeutics PTHS
NYSE PTHS
$8.72 -0.18 (-2.02%)
As of: Nov 11, 2026 · 10:15 AM EST

Pelthos Therapeutics (PTHS) Return on Equity [ROE] (2024 - 2026)

Updated

Pelthos Therapeutics' Return on Equity [ROE] was -972.61% in Q2 2026, down 744.14 percentage points from the prior quarter.

Analysis

Pelthos Therapeutics (PTHS) Return on Equity [ROE] (2024 - 2026) Analysis & Trends

For FY2025, Return on Equity [ROE] at Pelthos Therapeutics came in at -239.55%.

  • The Q2 2026 figure marks the lowest quarterly Return on Equity [ROE] since Q2 2024.
  • Per Business Quant data, PTHS's Return on Equity [ROE] in the three quarters before Q2 2026 was -228.47% (Q1 2026), -89.19% (Q4 2025) and -91.12% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 74.39%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 19.33%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 5.63%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 21.60%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 72.13%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -31.17%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 4.66%
10 Pelthos Therapeutics 33.36 Mn -55.04 Mn 11.99 Mn -949.21%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -949.21%
Mar 31, 2026 -220.94%
Dec 31, 2025 -89.19%
Sep 30, 2025 -91.12%
Jun 30, 2024 -2,070.79%
API Access

Pelthos Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=PTHS&period=max&api_key=YOUR_API_KEY